Chugai Pharmaceutical Co., Ltd.
4519.T · JPX
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | ¥11,517,806,364 | ¥8,788,706,478 | ¥5,539,679,664 | ¥6,140,900,250 |
| - Cash | ¥540,202,000 | ¥458,674,000 | ¥222,169,000 | ¥267,753,000 |
| + Debt | ¥10,897,000 | ¥13,455,000 | ¥14,109,000 | ¥16,040,000 |
| Enterprise Value | ¥10,988,501,364 | ¥8,343,487,478 | ¥5,331,619,664 | ¥5,889,187,250 |
| Revenue | ¥1,170,611,000 | ¥1,111,367,000 | ¥1,259,946,000 | ¥999,758,000 |
| % Growth | 5.3% | -11.8% | 26% | – |
| Gross Profit | ¥830,749,000 | ¥693,009,000 | ¥783,062,000 | ¥660,268,000 |
| % Margin | 71% | 62.4% | 62.2% | 66% |
| EBITDA | ¥574,796,000 | ¥475,644,000 | ¥562,660,000 | ¥450,301,000 |
| % Margin | 49.1% | 42.8% | 44.7% | 45% |
| Net Income | ¥387,317,000 | ¥325,472,000 | ¥374,429,000 | ¥302,995,000 |
| % Margin | 33.1% | 29.3% | 29.7% | 30.3% |
| EPS Diluted | 235.36 | 197.8 | 227.57 | 184.17 |
| % Growth | 19% | -13.1% | 23.6% | – |
| Operating Cash Flow | ¥447,600,000 | ¥409,925,000 | ¥244,112,000 | ¥279,626,000 |
| Capital Expenditures | -¥50,925,000 | -¥74,258,000 | -¥71,239,000 | -¥72,866,000 |
| Free Cash Flow | ¥396,675,000 | ¥335,667,000 | ¥172,873,000 | ¥206,760,000 |